AssureCKD and University of Manitoba Sign Exclusive, Global License Agreement for Kidney Screening and Diagnostic Technology
AssureCKD today announced it has entered into an exclusive global licensing agreement with the University of Manitoba, securing rights to a portfolio of patented and patent-pending microfluidic technologies for chronic kidney disease (CKD) screening and diagnosis.
The licensed intellectual property covers three complementary innovations:
Passive Mixing Microfluidic Urinary Albumin Chip (UAL-chip): designed for precise CKD assessment.
Microfluidic Urine Albumin/Creatinine Chip (uACR-chip): enabling rapid, quantitative testing.
Paper-Based Microfluidic Cystatin C Chip (Cys-C chip): allowing measurement of cystatin C in plasma and serum.
Developed by University of Manitoba researchers including Dr. Francis Lin, Dr. Paul Komenda, Dr. Claudio Rigatto, and Dr. Navdeep Tangri, these technologies form the core of AssureCKD’s MATLOC system, a portable, integrated platform for kidney screening and diagnosis at the point-of-care.
“This agreement gives us the exclusive rights we need to bring these innovations out of the lab and into clinics around the world,” said Harrison Ross, CEO of AssureCKD. “And by bringing lab-equivalent results to the point-of-care, we make early CKD detection routine, accessible, and easy.”
The license provides AssureCKD with the exclusive right to manufacture, market, and sell the technology worldwide for CKD diagnostics, positioning the company to accelerate product development, secure regulatory clearances, and prepare for commercialization.
About AssureCKD
AssureCKD is developing MATLOC, a lab-equivalent diagnostic platform designed to screen, diagnose, and monitor chronic kidney disease at the point-of-care. By enabling rapid, accessible, and cost-effective testing in primary care and decentralized settings, AssureCKD aims to increase screening rates and facilitate earlier intervention, ultimately improving outcomes and reducing expensive healthcare costs.